The need for screening and early intervention of metabolic dysfunction-associated steatotic liver disease in diabetes patients:an interpretation on the consensus of the American Diabetes Association
WANG Yun
XU Zhangrong
ZHANG Lili
Abstract：In May 2025,Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)in People with Diabetes:the Need for Screening and Early Intervention.A Consensus of the American Diabetes Association,was published in Diabetes Care.This consensus elaborates on the reasons for nomenclatural changes in MASLD,how to conduct risk stratification,current treatments and long-term monitoring and the importance of managements of MASLD by a multi-disciplinary professional team.In this paper,the authors interpret this consensus by combining the recent expert consensuses and clinical guidelines on diabetes complicated with MASLD at home and abroad,hoping to improve the understanding of MASLD and the disease risks associated with MASLD,and to screen,diagnose,treat and standardly manage prediabetes and type 2 diabetes mellitus(T2DM)patients complicated with MASLD at an early stage.
Keywords：Metabolic dysfunction-associated steatotic liver disease(MASLD)Liver fibrosisLiver cirrhosisPrediabetesDiabetes
Publication Date：2026-02-28
Online Publishing Date：2026-03-31(First online date of this platform, not the publication date of the document)
Pages：7( 128-134 )